The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Who Survived to 100-Days Post-transplant
Timeframe: 100 days post date of peripheral blood transplant
Number of Participants Who Survived to One Year Post-Transplant.
Timeframe: One year post date of peripheral blood transplant
Number of Participants Who Experienced a Successful Engraftment
Timeframe: Post-peripheral blood transplant
Number of Participants Who Achieved a Response to Treatment at 100 Days
Timeframe: 100 days post-peripheral blood transplant
Number of Participants Who Achieved a Response to Treatment at One Year
Timeframe: One year post-peripheral blood transplant
Number of Participants Who Experienced Toxicities Associated With This Treatment Regimen
Timeframe: Post-peripheral blood transplant
Number of Participants Who Had Incidence of Acute GVHD
Timeframe: Post-peripheral blood transplant
Number of Participants Who Had Incidence of Chronic GVHD
Timeframe: Post-peripheral blood transplant
Number of Participants Who Experienced Donor-Recipient Chimerism Following Transplant at Days 30, 60, and 90.
Timeframe: Days 30, 60, and 90 post-peripheral blood transplant
Number of Participants Who Experienced Treatment-Related Mortality Within the First 100 Days
Timeframe: 100 days post-peripheral blood transplant